索拉非尼在肝细胞癌患者中的临床效果及弥散加权成像影像学特点研究

Clinical Effect and Diffusion Weighted Imaging Characteristics of Sorafenib on Patients with Hepatocellular Carcinoma

目的探讨索拉非尼在肝细胞癌患者中的临床效果及弥散加权成像(DWI)影像学特点。方法选取我院收治的肝细胞癌患者114例,随机分为两组。对照组应用经导管肝动脉化疗栓塞(TACE)治疗,观察组在对照组的基础上联合应用索拉非尼治疗。观察对比两组患者治疗前后细胞免疫功能指标变化,以及治疗后的肿瘤病灶ADC值、生存率、不良反应。结果治疗后,观察组患者CD^(8+)水平显著低于对照组(P<0.05);CD^(3+)、CD^(4+)、CD^(4+)/CD^(8+)水平显著高于对照组(P<0.05),肿瘤病灶的ADC值显著高于对照组(P<0.05),生存率显著高于对照组(P<0.05),不良反应发生率显著高于对照组(P<0.05),其中手足综合征发生率最高。结论索拉非尼能有效改善患者的免疫功能,提高其临床治疗效果;DWI成像能够客观地评估肝细胞癌患者的临床疗效,为下一步治疗提供参考。

Objective To investigate the clinical efficacy and diffusion-weighted imaging features of sorafenib on patients with hepatocellular carcinoma.Methods A total of 114 patients with hepatocellular carcinoma admitted to our hospital were randomly divided into two groups.The control group was treated with transcatheter arterial chemoembolization(TACE).The observation group got TACE treatment combined with sorafenib.Observe and compare the changes of cellular immune function before and after treatment in both groups of hepatocellular carcinoma patients.The ADC values of tumor lesions,survival rates and adverse reactions after treatment were also compared between the two groups.Results After treatment,the level of CD8+of patients in observation group was lower than that in control group(P<0.05).The CD3+and CD4+levels and CD4+/CD8+were higher in observation group than in control group(P<0.05).ADC values of lesions in patients of observation group were higher than those of control group(P<0.05).The survival rate in the observation group was also higher than in the control group(P<0.05).However,the incidence of adverse reaction in the observation group was higher than in the control group,and hand-foot syndrome had the highest incidence in the observation group(P<0.05).Conclusion Sorafenib can effectively improve the immune function and strengthen the clinical therapeutic effect of hepatocellular carcinoma patients.DWI imaging can objectively evaluate the clinical therapeutic effect and provide reference for next treatment.